508 completed, 127 terminated, 112 recruiting, 92 unknown. 434 Phase 1, 419 Phase 2, 76 Phase 3, 70 Not applicable, 29 Early Phase 1.
Follow Burkitt Lymphoma: new trials by email Literature Review of Burkitt Lymphoma trials Research Report on Burkitt Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| BLinatumomab and iNKT in Relapsed B-Cell ALL Invariant Natural Killer T Cell Therapy - B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia) | Phase 1 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 13 | 2026-10-01 | 2026-10-09 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-10-01 | 2026-08-18 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T) - Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL) | Not applicable | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2026-09-01 | 2026-02-17 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-09-01 | 2026-08-11 |
| Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 228 | 2026-09-01 | 2026-08-10 |
| SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia SNC116 - B-cell Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Shanghai Simnova Biotechnology Co.,Ltd. | 28 | 2026-09-01 | 2026-09-21 |
| CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukaemia | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 107 | 2026-09-01 | 2026-06-03 | |
| Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-08-26 | 2026-10-15 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL Antigen-specific T cells CART/CTL and DCvac - B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-08-24 |
Showing 20 of 972. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (584) · Lymphoma, Large B-Cell, Diffuse (570) · Lymphoma, Follicular (521) · Lymphoma, Mantle-Cell (507) · Lymphoma, Non-Hodgkin (495) · Leukemia, Lymphocytic, Chronic, B-Cell (464) · Lymphoma, B-Cell, Marginal Zone (458) · Lymphoma, Large-Cell, Immunoblastic (445) · Lymphoma (438) · Hodgkin Disease (346) · Leukemia (266) · Lymphoma, T-Cell, Cutaneous (252) · Leukemia, Myeloid, Acute (251) · Multiple Myeloma (248)
DNA Virus Infections (972) · Hemic and Lymphatic Diseases (972) · Herpesviridae Infections (972) · Tumor Virus Infections (972) · Immune System Diseases (971) · Immunoproliferative Disorders (971) · Virus Diseases (971) · Neoplasms by Histologic Type (970) · Lymphatic Diseases (969) · Epstein-Barr Virus Infections (968) · Infections (950) · Lymphoproliferative Disorders (938) · Neoplasms (916) · Lymphoma, B-Cell (895) · Hematologic Diseases (705)
Cyclophosphamide (223) · Rituximab (112) · Etoposide (101) · Peripheral Blood Stem Cell Transplantation (94) · Vincristine (94) · Cytarabine (93) · Methotrexate (92) · Filgrastim (91) · fludarabine phosphate (85) · Doxorubicin (70) · Prednisone (68) · Radiotherapy (67) · Dexamethasone (59) · Cyclosporine (53) · Mycophenolic Acid (53)
National Cancer Institute (NCI) (112) · Fred Hutchinson Cancer Center (59) · M.D. Anderson Cancer Center (34) · City of Hope Medical Center (28) · Memorial Sloan Kettering Cancer Center (27) · Masonic Cancer Center, University of Minnesota (25) · Children's Oncology Group (24) · Case Comprehensive Cancer Center (22) · Roswell Park Cancer Institute (16) · Mayo Clinic (15) · National Institutes of Health Clinical Center (CC) (14) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (14) · Alliance for Clinical Trials in Oncology (13) · Medical College of Wisconsin (13) · Northwestern University (13)
United States (722) · China (100) · Canada (62) · France (41) · Italy (41) · United Kingdom (36) · Germany (34) · Australia (28) · Puerto Rico (26) · Spain (24) · Switzerland (23) · Netherlands (21) · Belgium (17) · South Korea (14) · Israel (13)
Ajay Gopal (9) · Elias Jabbour (7) · Philip L. McCarthy, MD (6) · Christos E. Emmanouilides, MD (5) · David Maloney (5) · Elias Jabbour, MD (5) · Ibrahim Aldoss (5) · Roger Strair, MD, PhD (5) · Brenda Sandmaier (4) · Claudio G. Brunstein, MD, PhD (4) · Ephraim J. Fuchs, MD (4) · Julie M Vose, MD (4) · Kenneth G. Lucas, MD (4) · Shivaani Kummar, MD (4)
PMID 41671463, PMID 35622074, PMID 34515338, PMID 32499241, PMID 32589970, PMID 38551807, PMID 17242396, PMID 19949018, PMID 20028764, PMID 21527516, PMID 22002018, PMID 22337718, PMID 24862638, PMID 33308471, PMID 33496754, PMID 34353848, PMID 34432863, PMID 34687939, PMID 34889384, PMID 35422096, PMID 37486616, PMID 37890117, PMID 39121442, PMID 40367950, PMID 42341322, PMID 10552943, PMID 10632319, PMID 10764422, PMID 10820362, PMID 11410496, PMID 11600602, PMID 11756154, PMID 12121233, PMID 12171484, PMID 12525530, PMID 1403051, PMID 14508361, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15042678, PMID 15107815, PMID 15459300, PMID 15466923, PMID 15570084, PMID 15914552, PMID 16135477, PMID 16148284, PMID 16966261, PMID 17119113
P30CA033572 (24), P30CA015704 (19), P30CA043703 (17), U10CA032102 (15), P30CA006973 (13), P30CA015083 (12), U10CA180886 (12), P30CA022453 (11), P30CA072720 (9), U01CA097452 (9), U10CA098543 (9), P30CA016672 (8), P30CA068485 (7), U10CA031946 (7), 2023 (6)